SCHEMBL15548809

SCHEMBL15548809

Cc1c(C(=O)Nc2ccc(O)c(Cl)c2)c(=O)n(-c2ccccc2)n1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.58
POLB P06746 1/20 0.58
ALDH1A1 P00352 2/20 0.53
GAA P10253 1/20 0.53
MET P08581 7/20 0.52
KDR P35968 6/20 0.52
FPR2 P25090 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
PKM P14618 1/20 0.52
TP53 P04637 1/20 0.51
HSD17B10 Q99714 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
IGF1R P08069 4/20 0.50
AURKA O14965 1/20 0.50
JAK2 O60674 1/20 0.50
RPS6KA5 O75582 1/20 0.50
ABL1 P00519 1/20 0.50
INSR P06213 1/20 0.50
LCK P06239 1/20 0.50
RET P07949 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15559122 0.88 MET (0.61) METKDRFPR2TP53HSD17B10
SCHEMBL15559177 0.84 FPR2 (0.56) MAPTALDH1A1METKDRFPR2
SCHEMBL21294459 0.84 TP53 (0.61) MAPTPOLBALDH1A1METKDR
SCHEMBL22418428 0.81 FPR2 (0.69) MAPTGAAMETKDRFPR2
SCHEMBL2955823 0.80 MET (0.61) METKDRFPR2TP53HSD17B10
SCHEMBL15560337 0.79 TP53 (0.54) MAPTPOLBALDH1A1GAAMET
SCHEMBL15558947 0.79 MET (0.69) METKDRIGF1RAURKAJAK2
SCHEMBL27936346 0.77 TP53 (0.60) MAPTPOLBALDH1A1GAAMET
SCHEMBL15559994 0.76 TP53 (0.56) MAPTALDH1A1METKDRFPR2
SCHEMBL15560739 0.76 MET (0.83) METKDRIGF1RAURKAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2879676-B1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES LLC (US) 2017-06-14 EP disclosed
EP-2879677-B1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES LLC (US) 2017-06-14 EP disclosed
US-9326975-B2 Substituted pyrazolone compounds and methods of use SUNSHINE LAKE PHARMA CO., LTD (CN) 2016-05-03 US disclosed
EP-2879676-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE Calitor Sciences, LLC (US) 2015-06-10 EP disclosed
EP-2879677-A2 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE Calitor Sciences, LLC (US) 2015-06-10 EP disclosed
US-20150141463-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-05-21 US disclosed
US-8975282-B2 Substituted pyrazolone compounds and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-10 US disclosed
US-8969388-B1 Substituted pyrazolone compounds and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-03 US disclosed
US-20150050239-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-02-19 US disclosed
US-20150037280-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-02-05 US disclosed
CN-103565653-A Substituted pyrazolone compound as well as using method and application of pyrazolone compound SUNSHINE LAKE PHARMA CO LTD 2014-02-12 CN disclosed
WO-2014022116-A2 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2014-02-06 WO disclosed
WO-2014022117-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2014-02-06 WO disclosed
WO-2013180949-A1 SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE XI NING (US) 2013-12-05 WO disclosed
CN-103420986-A Substituted quinoline compounds, methods of use, and uses thereof GUANGDONG HEC PHARMACEUTICAL 2013-12-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150037280-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE MKI67, PRKACA, PRKDC MAPT 4420/4885POLB 2212/4885ALDH1A1 2913/4885
US-20150141463-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE MKI67, PRKACA, PRKDC MAPT 4420/4885POLB 2212/4885ALDH1A1 2913/4885
US-20150050239-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE MKI67, PRKACA, PRKDC MAPT 4420/4885POLB 2212/4885ALDH1A1 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.